Inequities exist in all aspects of diabetes care. In this article, Alesha Smith outlines some examples, proposes some actions, and explains where the new medicines fit in.
Click the LET’S LEARN button at the bottom of the article to go through to ELearning and complete a quiz to test your knowledge.
Pharmacists can claim 1 group 2 ENHANCE point for successful completion of the quiz. Nurses and GPs can add the learning to their professional development or CME profiles respectively.
Late last year, PHARMAC announced the SGLT2 inhibitor empagliflozin (Jardiance®) and empagliflozin with metformin (Jardiamet®) will be funded for the treatment of type 2 diabetes under Special Authority.
Find out all you need to know about the Special Authority criteria.
If you are a GP practising in New Zealand and would like to use a data analytics tool that can help you assess your prescribing with respect to type-2 diabetes, and allow you to compare your prescribing behaviour to your peers, then sign up now. To sign up to EPiC, simply click here to begin the two-step sign up process.